Why the study?
To evaluate the prevalence of carotid intima-media thickness and plaques in persons living with HIV, assessing the impact of cardiovascular risk factors, antiretroviral regimens, and treatment status.
In persons living with HIV, there is a high prevalence (30.2%) of carotid atherosclerotic lesions, which are associated with traditional risk factors, low CD4+ nadir, and raltegravir use.
May support CV risk assessment in PLWHIV; leaves open differential effects of ART regimens and treatment experience on carotid lesions.
Objectives To evaluate the prevalence of carotid intima-media thickness and plaques in a cohort of persons living with HIV, the role of cardiovascular risk factors, the impact of the antiretroviral regimens, and the difference between naïve and experienced patients in the onset of carotid lesions. Methods This project was initiated in 2019 and involves eight Italian Centers. Carotid changes were detected using a power color-Doppler ultrasonography with 7.5 MHz probes. The following parameters are evaluated: intima-media thickness of both the right and left common and internal carotids: Data regarding risk factors for CVD, HIV viral load, CD4+ cell counts, serum lipids, glycaemia, and body mass index. The associations between pathological findings and potential risk factors were evaluated by logistical regression, with odds ratios (OR) and 95% confidence intervals (95% CI). Results Among 1147 evaluated patients, aged 52 years on average, 347 (30.2%) had pathological findings (15.8% plaques and 14.5% IMT). Besides usual risk factors, such as older age, male sex, and dyslipidemia, CD4+ cell nadir <200 cells/mL (OR 1.51, 95% CI 1.14-1.99) and current use of raltegravir (OR 1.54, 95% CI 1.01-2.36) were associated with higher prevalence of pathological findings. Conclusions Our data show that the overall percentage of carotid impairments nowadays remains high. Color-Doppler ultrasonography could play a pivotal role in identifying and quantifying atherosclerotic lesions among persons living with HIV, even at a very premature stage, and should be included in the algorithms of comorbidity management of these patients.
No takes yet. Share an insight, caveat, or question.
Maggi et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: